Business Context and Reporting Period
This filing is a Form 10-K for Histogenics Corporation, not Ocugen, Inc., covering the fiscal year ended December 31, 2017. The company was a clinical-stage biotechnology company developing restorative cell therapies, principally NeoCart, an autologous cartilage-repair product candidate for knee defects. The filing was signed March 15, 2018.
NeoCart was in a completed-enrollment, 249-patient Phase 3 trial under an FDA Special Protocol Assessment. The company had no FDA-approved products and no product sales revenue.
Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $15.6 million | $21.6 million | Down 28% |
| General and administrative expense | $9.4 million | $8.5 million | Up 10% |
| Total operating expenses | $25.0 million | $30.3 million | Down $5.4 million |
| Net loss | $26.4 million | $16.2 million | Loss increased $10.2 million |
| Basic loss per share | $0.99 | $0.97 | Loss per share increased |
| Cash used in operating activities | $23.0 million | $25.7 million | Improved $2.7 million |
| Cash, cash equivalents and marketable securities | $8.0 million | $31.9 million in cash and equivalents | Significant decline |
| Total liabilities | $22.3 million | $22.5 million | Broadly stable |
| Warrant liability | $14.7 million | $13.2 million | Up $1.5 million |
| Equipment loan | $0.2 million | $0.8 million | Down $0.6 million |
Stockholders’ equity was negative $11.3 million at December 31, 2017, compared with positive equity of $13.6 million at December 31, 2016. The company reported an accumulated deficit of $208.2 million.
The 2017 net loss included a $1.5 million unfavorable change in the fair value of warrant liabilities. The 2016 results benefited from a $17.5 million favorable warrant-liability adjustment and included $3.1 million of warrant expense, making year-over-year net loss comparisons less indicative of operating performance.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined by $6.0 million, primarily due to lower collaboration, consulting, clinical trial, recruitment, personnel and clinical-material costs.
- General and administrative expense increased by $0.9 million, driven by higher personnel, professional-fee and facility costs.
- Operating cash burn improved by $2.7 million, but the company’s cash position fell sharply because 2016 included $27.6 million of net private-placement proceeds while 2017 had no comparable financing.
- NeoCart Phase 3 enrollment was completed in the second quarter of 2017, with 169 patients assigned to NeoCart and 80 to microfracture across 36 sites.
- In December 2017, the company granted MEDINET exclusive NeoCart commercialization rights in Japan. The agreement provided for a $10.0 million non-refundable upfront payment, up to $76.9 million of additional milestone payments, supply payments and tiered royalties. The upfront payment was received on January 5, 2018 and was not recognized as revenue in 2017.
- The company early adopted ASC 606 using the modified retrospective method. It expected to recognize the MEDINET upfront amount over approximately two years beginning when the Japanese clinical trial and related manufacturing services commenced.
- Subsequent to year-end, the company completed a January 2018 registered direct offering that generated approximately $5.9 million of net proceeds.
Guidance, Outlook, Risks and Unusual Items
- Management expected top-line one-year Phase 3 superiority data in the third quarter of 2018 and a potential FDA BLA submission in the third quarter of 2018, subject to positive results.
- If approved, management anticipated a potential U.S. commercial launch in 2019, but emphasized that approval was uncertain.
- The company expected its available resources, including the MEDINET upfront payment and January 2018 financing, to fund operations into the fourth quarter of 2018. The filing states that these conditions raised substantial doubt about the company’s ability to continue as a going concern.
- NeoCart’s FDA approval depended on successful Phase 3 results, completion of manufacturing technology transfers, FDA acceptance of comparability for internally manufactured collagen, scaffolds and adhesive components, and successful manufacturing inspections.
- The company had previously paused manufacturing and Phase 3 enrollment in 2012 after identifying testing discrepancies involving bovine-derived collagen. Operations resumed after manufacturing and quality-system upgrades, but similar manufacturing, quality and supply risks remained.
- Commercial success depended on regulatory approval, reimbursement, physician and patient adoption, manufacturing scale, pricing, competition and additional financing.
- The company had no pending litigation disclosed and no off-balance-sheet arrangements. It was in compliance with its equipment-loan covenants at year-end.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern emphasis. The auditor noted that total liabilities exceeded total assets by $11.3 million at December 31, 2017.
Most Important Facts for Investors to Verify
- Verify the issuer identity: the supplied filing is for Histogenics Corporation, while the request identifies Ocugen, Inc.
- Verify the final NeoCart Phase 3 results, FDA BLA filing status and regulatory outcome after 2017.
- Verify whether MEDINET commenced the Japanese clinical program and the timing and amount of revenue recognized from the $10.0 million upfront payment.
- Verify subsequent financing, cash balances, operating burn and whether the going-concern uncertainty was resolved.
- Review warrant terms, potential dilution from approximately 13.6 million warrant shares, approximately 2.0 million shares issuable on preferred-stock conversion, and outstanding options.
- Assess whether manufacturing comparability, facility qualification, supply capacity and reimbursement requirements were satisfied.
- Confirm current corporate status and any merger, name-change or other transaction that may explain the mismatch between Histogenics and Ocugen.